Get notified when INDP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The auditor's report includes an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.
Indaptus Therapeutics launches $2.34M at-the-market offering; shares sold at market prices
Filed September 2, 2025 · ~1 min read
Key Changes
-
high
Indaptus is selling up to $2.34M of common stock via an at-the-market offering with H.C. Wainwright as sales agent, paying a 3.0% commission.
The Offering verify on EDGAR → -
medium
Net proceeds will fund R&D, clinical trials, manufacturing, working capital, and general corporate purposes, with management retaining broad discretion.
Use of Proceeds verify on EDGAR → -
high
New investors pay $7.07/share but receive only $4.343/share in net tangible book value, an immediate dilution of $2.73 per share.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade INDP commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify